Advertisement
Australia markets closed

  • ALL ORDS

    8,082.30
    -67.80 (-0.83%)
     

  • ASX 200

    7,814.40
    -66.90 (-0.85%)
     

  • AUD/USD

    0.6695
    +0.0015 (+0.22%)
     

  • OIL

    80.00
    +0.77 (+0.97%)
     

  • GOLD

    2,419.80
    +34.30 (+1.44%)
     

  • Bitcoin AUD

    99,871.20
    +2,297.09 (+2.35%)
     

  • CMC Crypto 200

    1,369.64
    -4.20 (-0.31%)
     

  • AUD/EUR

    0.6155
    +0.0016 (+0.26%)
     

  • AUD/NZD

    1.0905
    -0.0001 (-0.01%)
     

  • NZX 50

    11,699.79
    -28.27 (-0.24%)
     

  • NASDAQ

    18,546.23
    -11.73 (-0.06%)
     

  • FTSE

    8,420.26
    -18.39 (-0.22%)
     

  • Dow Jones

    40,003.59
    +134.21 (+0.34%)
     

  • DAX

    18,704.42
    -34.39 (-0.18%)
     

  • Hang Seng

    19,553.61
    +177.08 (+0.91%)
     

  • NIKKEI 225

    38,787.38
    -132.88 (-0.34%)
     

Compared to Estimates, AdvanSix (ASIX) Q1 Earnings: A Look at Key Metrics

Zacks Equity Research
·2-min read

For the quarter ended March 2024, AdvanSix (ASIX) reported revenue of $336.83 million, down 15.9% over the same period last year. EPS came in at -$0.56, compared to $1.30 in the year-ago quarter.

The reported revenue represents a surprise of -2.26% over the Zacks Consensus Estimate of $344.63 million. With the consensus EPS estimate being -$0.54, the EPS surprise was -3.70%.

While investors closely watch year-over-year changes in headline numbers -- revenue and earnings -- and how they compare to Wall Street expectations to determine their next course of action, some key metrics always provide a better insight into a company's underlying performance.

As these metrics influence top- and bottom-line performance, comparing them to the year-ago numbers and what analysts estimated helps investors project a stock's price performance more accurately.

ADVERTISEMENT

Here is how AdvanSix performed in the just reported quarter in terms of the metrics most widely monitored and projected by Wall Street analysts:

  • Sales- Nylon: $84.39 million compared to the $75.20 million average estimate based on two analysts. The reported number represents a change of -15.1% year over year.

  • Sales- Ammonium Sulfate: $85.26 million versus $94.80 million estimated by two analysts on average. Compared to the year-ago quarter, this number represents a -25.4% change.

  • Sales- Chemical Intermediates: $105.70 million versus $98.98 million estimated by two analysts on average. Compared to the year-ago quarter, this number represents a -7.7% change.

  • Sales- Caprolactam: $61.48 million compared to the $57.90 million average estimate based on two analysts. The reported number represents a change of -15.1% year over year.

View all Key Company Metrics for AdvanSix here>>>

Shares of AdvanSix have returned -7% over the past month versus the Zacks S&P 500 composite's -2.7% change. The stock currently has a Zacks Rank #1 (Strong Buy), indicating that it could outperform the broader market in the near term.

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report

AdvanSix (ASIX) : Free Stock Analysis Report

To read this article on Zacks.com click here.

Zacks Investment Research